Search results

Combining scientific expertise with more than $1.3 billion in unique operational assets to provide optimal radioactive waste solutions.

Researchers from the Health Research and Technology Group at ANSTO and the University of Wollongong have developed a new device that could improve the quality control of accelerator-based boron neutron capture therapy, a promising radiation therapy for treating aggressive cancers. 

Our people, the custodians of Australia’s nuclear and accelerator expertise, are amongst our nation’s most talented researchers, scientists, engineers and nuclear experts. Everyday we work to respond to the growing nuclear science and technology needs of Australia and the world.

ANSTO offers accelerator-based particle-induced gamma-ray emission techniques to determine total fluorine concentration in a range of solid materials and rapidly screen for the presence of PFAS (perfluoroalkyl and polyfluoroalkyl substances).

To enable the production of nuclear medicine, ANSTO operates manufacturing, processing and distribution facilities in Sydney.

ANSTO researchers have demonstrated longstanding expertise in the study of nuclear fuel and radioactive waste with two recent journal articles in a special issue of Frontiers of Chemistry.

An investment that will secure the long term sustainability of nuclear medicine supply in Australia.

2022 has been a big year for ANSTO with contributions to the advanced manufacturing, space, food, energy industries, and more. As we set our sights on 2023, we thought we’d take the opportunity to share some of our key innovation achievements from this year.

ANSTO is dedicated to identifying opportunities for the application of knowledge and technology developed by the organisation for a wide range of industry applications.

ANSTO drives Australian innovation through partnerships designed to respond to the needs of industry. Get in touch to discuss business opportunities today.

University of Melbourne researchers have investigated a method to produce magnetic nanoparticles in Australia for use in COVID-19 PCR tests.